Clinical Trial Update: Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 neoadjuvant trial evaluating DPX-Survivac with an aromatase inhibitor, radiotherapy, or cyclophosphamide in hormone receptor-positive, HER2-negative bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DPX-Survivac

Snippet

Sponsor: Providence Health & Services | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING